Felix is a pharmacist by training with a PhD in pharmacology. In 2006, he joined Boehringer Ingelheim as a trainee, focusing on launch and transfer activities of inhalative products. He then took over different roles at BI microParts in Dortmund at the development site of inhalation devices as development QA manager, senior project manager, and lab head of device development. In 2010, he joined the Ger­resheimer Group at Bünde as a QC head and later on as quality director. Buende is a large-scale manufacturing site of sterile primary packaging components, i.e.RTF®- syringes and insulin cartridges. In 2015, he returned to Boehringer Ingelheim to implement systems for systematic lifecycle management of the Respimat® Plat­form Technology, including ownership of the design history files. Currently, he is the director of product- & process-technology including responsibilities for project management, design verification laboratories, clinical trial supply, and design & process technology of devices.

Dr. Stefan Leiner is a pharmacist by training and joined Boehringer Ingelheim in Germany in 1987. After a couple of years in manufacture, pharmaceutical and analytical development, he focussed on inhalation forms. He is responsible for the scientific standard of the module 3 of marketing authorisation applications. He authored the quality overall summaries for a lot of Boehringer Ingelheim’s inhalation developments. Stefan represents Boehringer Ingelheim in the Inter­national Pharmaceutical Aerosol Consortium – Regulation and Science (IPAC-RS) and was chair of that organisation. He was a member of the development group of the ISO 20072 Standard on ‘Aerosol Drug Delivery Devices.’ He is active in pharmacopeias.

Diana A. Fernandes holds a MSc Degree in Biological Engineering by Instituto Su­perior Técnico, University of Lisbon, 2015. She joined Hovione in the same year as an Industrial PhD Candidate in collaboration with Faculty of Pharmacy, Uni­versity of Lisbon, specializing in spray dried composite formulations for dry pow­der inhaler delivery of biopharmaceuticals, namely enzymes. Since 2018, Diana has also been working as an Inhaled Biopharmaceutical Formulation Scientist at Hovione R&D Drug Product Development Department, supporting the develop­ment and tech-transfer of Spray Drying and Jet Milling projects of inhalable clini­cal products ranging from small to large molecules, from lab to industrial scales.

She was one of the recipients of the prize for Women in Science at the 22nd Congress of the International Society for Aerosols in Medicine (ISAM), Montreux, Switzerland this year

Ignasi Escamilla became a chemical engineer at the Institut Químic de Sarrià after earning a bachelor’s degree in chemical sciences at Ramon Llull Uni­versity. He joined the pharmaceutical industry in 1997 and worked as a bioana­lyst in the PK department for four years at J.URIACH & Cia. Afterwards he worked as a formulation development manager at ISDIN for almost nine years, with the pharmaceutical development of topical application drug products, including new transdermal delivery systems as main responsibilities. In 2010, Ignasi joined Fer­rer Internacional as a formulation development manager for non-conventional pharmaceutical forms and project manager for the project and alliances develop­ment department. He’s been involved in the development of inhaled products since 2012, becoming in 2016 the inhalation and sterile technology manager. He covered practically all aspects of the development of inhaled products, most prominently solid-state analysis, pharmaceutical formulation, industrialisation and development of devices the most relevant among them.

In his role, David Roe and his team oversee operational and life cycle mainte­nance activities related to medical devices and combination products at Novartis globally. His team supports multiple development programs and projects contain­ing medical devices and or combination products. He has over 25 years of experi­ence in R&D and manufacturing within the consumer electronics, medical devices and pharmaceutical industries. Before joining Novartis, he held several roles in Fortune 100 companies including West Pharmaceuticals, Apple and General Elec­tric, focussing on the development and commercialisation of pharmaceutical de­livery systems and consumer electronics.

Dr. Gerhard Pohlmann (Division Director Translational Medical Engineering; Fraunhofer ITEM) has degrees in chemistry and chemical engineering. He has over 35 years of experience in aerosol and inhalation technology. Importantly, he worked more than 10 years with Takeda on the development of the CPA technol­ogy described herein. He is a member of academic societies. Since 20 years, he holds various senior management positions in particular at Fraunhofer ITEM at Hannover, has more than 15 years of experience in developing medical devices from project start and holds a key position within the CPA Team. He teaches at the University of Applied Sciences Wilhelmshaven.

Dr. Peter Daley-Yates is Director of Clinical Pharmacology and Experimental Medi­cine at GlaxoSmithKline. His expertise lies in clinical pharmacology and pharma­cokinetics/ pharmacodynamics with a focus on respiratory diseases, mechanisms of inflammation and drug action, inhaled drug delivery and metabolomics. Dr. Daley-Yates joined the pharmaceutical industry in 1991 - initially at Upjohn, then Pharmacia & Upjohn, before moving to GlaxoWellcome in 1996. Prior to that, he held several academic and industry-funded doctoral and post-doctoral research posts, before being appointed Lecturer in the Department of Pharmacy at Man­chester University in 1985. During his career to date, he has been instrumental in the successful development of drug products in oncology, infectious diseases, inflammation, allergy and respiratory diseases. He has authored more than 160 publications including original research, reviews, book chapters and patents.

Ben Forbes is Professor of Pharmaceutics at King’s College London. He has a BPharm from King’s College London (1987) and a PhD in Drug Delivery from Strathclyde University (1996). Before doctoral studies, he worked in hospital pharmacy in London and Sydney, and for Inveresk Clinical Research in Edinburgh. He was appointed to the academic staff of King’s College London in 1997 and is a registered pharmacist in the UK. Ben Forbes has authored many publications in Inhalation Biopharmaceutics, including: (1) inhaled medicine formulation, (2) the development and application of techniques to study respiratory drug trans­port and metabolism, (3) inhalation toxicology. He chairs the Scientific Advisory Committee of the Aerosol Society’s annual Drug Delivery to the Lung’s (DDL) conference in UK.

Beatriz Martin Yagüe is a pharmacist by training at the Pharmacy Faculty at the University of Barcelona where she specialized in Pharmaceutical Technology in 2000. She joined Novartis in 2014 at the facility site located in Barberà del Val­lès (Spain). Her experience includes over 20 years in pharmaceutical industry, as well as researcher in the University of Barcelona during her bachelor studies. Prior of belonging to Novartis, Beatriz worked at Almirall (a Spanish-based phar­maceutical company) for more than 15 years working on the pharmaceutical and analytical development of orally inhaled drug products. In this sense, she was responsible for the development of various NCEs and its combinations at Almi­rall understanding the different properties that are affecting the aerosol perfor­mance of such delivered dosage forms. She worked also on the optimization and scale-up processes of the dry powder inhalers products developed by Almirall. Her career at Novartis as Inhalation Technical and Product Steward is focused on the Manufacturing Science and Technology department (MS&T) where she is responsible for the set-up of the new inhalation manufacturing facility in Barberà del Vallès working during these years on the transfer-in of all Novartis inhalation portfolio. She is also responsible for improving its manufacturing processes and drug product performance by the appropriate statistical tools.

Andrew Dundon is the founder and owner of Pharmechceutics Ltd. an independent consultancy specialising in supporting clients to design, develop, register and industrialise robust, differentiated patient centric drug delivery systems. Andrew was formerly the Head of Device Engineering in the Product Development & Supply, GSK Research and Development. During a 20 year career within the GSK Device Engineering function, Andrew assumed roles of increasing responsibility.

Andrew joined GSK in January 1989. Initially, within the Inhalation Analysis De­partment where his formative years were involved in the development of Sal­meterol and Fluticasone in the Diskhaler™ and subsequently the Diskus™ drug delivery systems. In 1999, Andrew took a secondment opportunity in what would now be described as Device Engineering, thinking it would be an interesting short term secondment to broaden his experience of the product development pro­cess. Andrew has never regretted the move and has had the opportunity to lead or assume accountability for key deliverables in the development of the pMDI counter, Veramyst/Mistrpo™, Ellipta™ inhaler and a number novel drug delivery devices which are still in development. Andrew assumed leadership of the Device Engineering Group in September 2013. Andrew was formerly the Co-Chairperson of the IPAC-RS Devices Working Sub-Group between 2013-2019. Andrew has a real passion for how drug delivery systems should be most effectively developed from concept through the product lifecycle using a risk based approach informed by the regulatory framework, which he has used IPAC-RS to influence, within which companies are required to operate.